Hypogonadotropic hypogonadism as a cause of NOA and its treatment.

Hypogonadotropic hypogonadism (HH) is a correctable cause of nonobstructive azoospermia (NOA) that can be successfully treated with medical therapy in approximately 75% of cases.

• HH represents a 'relatively rare cause of nonobstructive azoospermia (NOA)'
• Medical therapy is effective in '3 quarters of cases'
• A 'small but significant proportion of patients do not achieve sufficient responses' to treatment
• Knowledge of HH is described as 'crucial for the clinical andrologists'

HH can be classified into congenital and acquired forms with distinct clinical presentations.

• Congenital HH includes anosmic HH (Kallmann syndrome, associated with absent sense of smell) and normosmic HH (not associated with anosmia)
• Congenital HH is characterized by 'complete absence of pubertal development'
• Acquired HH occurs after pubertal development and presents primarily with infertility and 'typical symptoms of late-onset hypogonadism'
• Patients with acquired HH seek medical assistance mainly due to infertility and late-onset hypogonadism symptoms

Gonadotropin-releasing hormone (GnRH) or gonadotropin replacement therapy is the primary treatment for HH-related NOA.

• GnRH or gonadotropin replacement therapy is described as 'the mainstay of drug therapy'
• These therapies 'offer excellent results' for HH patients
• Despite generally excellent results, a subset of patients fail to achieve sufficient therapeutic responses
• The treatment approach addresses the underlying hormonal deficiency rather than requiring surgical intervention